Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690235 · ClinicalTrials.gov registry record · Phase 4
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00690235 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT00690235, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.
Interventions
- DRUG Placebo
- DRUG Pramlintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690235
The ClinicalTrials.gov registry entry for NCT00690235 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00690235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690235 about?
NCT00690235 is a clinical study titled "Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia". Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.
What is the current status of trial NCT00690235?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2007-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00690235?
The interventions under investigation include: Placebo (DRUG), Pramlintide (DRUG).
Who is sponsoring clinical trial NCT00690235?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.